Novo Nordisk's Retatrutide Australia: A Potential Advancement for Weight Management?
Australia is eagerly awaiting the arrival of Retatrutide, a groundbreaking medication developed by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown remarkable efficacy in testing, suggesting a substantial influence on obesity. While still under review by the